Renal Cell Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
CK7 and α-methylacyl coenzyme A racemase are sensitive markers for papillary RCC; TFE3 expression is essential in confirming the diagnosis of Xp11 translocation RCC.
|
21204715 |
2011 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies.
|
27401463 |
2016 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Cytogenetic analysis revealed a karyotype of t(X;1)(p11.2; p34.3), consistent with a TFE3-associated RCC.
|
15383938 |
2005 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Cytogenetic studies confirmed the diagnosis of Xp11.2 translocation-associated RCC with positive TFE3 gene rearrangement.
|
28877071 |
2017 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Despite the numerous available drugs, the most appropriate treatments for patients affected by common or rare renal cell carcinomas (RCC), like those associated with the Xp11.2 translocation/transcription factor for immunoglobulin heavy-chain enhancer 3 (TFE3) gene fusion (TFE3 RCC), are not clearly defined.
|
24676409 |
2014 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Dual mTORC1/2 inhibition suppresses Akt/mTOR signaling more effectively than selective mTORC1 inhibition and demonstrates in vivo preclinical efficacy against TFE3-fusion renal cell carcinoma.
|
31519159 |
2019 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Dynamic Contrast-Enhanced CT Characterization of Xp11.2 Translocation/TFE3 Gene Fusions versus Papillary Renal Cell Carcinomas.
|
26636097 |
2015 |
Renal Cell Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Establishment and characterization of a renal cell carcinoma cell line (FU-UR-1) with the reciprocal ASPL-TFE3 fusion transcript.
|
15138551 |
2004 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Establishment of an ASPL-TFE3 renal cell carcinoma cell line (S-TFE).
|
23760492 |
2013 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Finally, pathologists should recognize that the histology of RCC associated with Xp11.2 translocation/TFE3 gene fusion may focally resemble that of chromophobe RCC, but TFE3 immunohistochemistry and molecular genetic study may be helpful in the differential diagnosis.
|
20683695 |
2010 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Follow-up period for patients with TFE3-rearranged RCC ranged from 0.8 to 16.5 years, with 4 of 6 dying from the disease.
|
22498819 |
2012 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Fusion of a novel gene, RCC17, to the TFE3 gene in t(X;17)(p11.2;q25.3)-bearing papillary renal cell carcinomas.
|
11358836 |
2001 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas.
|
8986805 |
1996 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we describe a case of TFE3-positive RCC in which metastatic relapse to the mediastinal lymph nodes and pulmonary nodules was treated with single-agent sunitinib, a multitargeted tyrosine inhibitor.
|
22995920 |
2013 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here, we describe a case of TFE3 translocation associated RCC in a 58-year-old patient, with emphasis on cytomorphologic features and clues toward this diagnostic entity.
|
29024535 |
2018 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Herein, we examined 5 additional cases of SFPQ-TFE3 RCCs using clinicopathologic, immunohistochemical, and molecular analyses.
|
28315422 |
2017 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
However, using immunohistochemistry, 9% of all renal cell carcinomas showed some degree of TFE3 reactivity.
|
22037260 |
2012 |
Renal Cell Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.
|
24339735 |
2013 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Importantly, reverse transcriptase-PCR showed concordant results with the results of FISH assay in the 8 available frozen cases.The break-apart and ASPL-TFE3 dual-fusion FISH assay can accurately detect the translocation of the TFE3 gene and ASPL-TFE3 fusion gene and can thus serve as a valid complementary method for diagnosing Xp11.2 tRCC and ASPL-TFE3 RCC.
|
25984679 |
2015 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In our laboratory, TFE3 is not diagnostic for Xp11.2 translocation RCC.
|
22523215 |
2012 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In the young patients with recurrence, the nephrectomy specimens were immunostained with TFE3 to determine the incidence of Xp11 translocation RCC.
|
21256565 |
2011 |
Renal Cell Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In this report, we found a rare case of RCC with a fusion between 5' EWSR1 and 3' TFE3.
|
31774608 |
2020 |
Renal Cell Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In this review of 168 pediatric RCC prospectively registered on Children's Oncology Group AREN03B2 protocol, six RCC (3.5%) that demonstrated a unique epithelioid morphology and a peculiar immunophenotypic profile that includes expression of ALK, TFE3, and retention of INI1 was identified.
|
26773439 |
2016 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Magnetic resonance imaging and computed tomography characteristics of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion.
|
24926688 |
2014 |
Renal Cell Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Magnetic resonance imaging findings of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in adults: a pilot study.
|
30019296 |
2019 |